The company said Ruxolitinib resulted in a "rapid and robust" clinical response, meeting its primary endpoint such as clear skin based on data from phase three study. The secondary endpoint -- the proportion of patients who achieved a 75% improvement in the eczema area -- was also met.
The overall safety profile was consistent with previous study data, with no new safety signals observed.
Price: 83.66, Change: +5.07, Percent Change: +6.45
|Consensus for Zumiez Q2 Earnings Raised but Full Yea...|
|Williams Sonoma's Q2, 2021, 2022 Full Year Earnings ...|
|Analysts' Ratchet Up 2020, 2021 Consensus Estimates ...|
|Q1, 2021, 2022 Earnings Estimates for Advanced Drain...|
|Q2 Projection for Westlake Chemical Increased but 20...|